197 related articles for article (PubMed ID: 34595541)
1. Vitiligo-like leukoderma as an indicator of clinical response to immune checkpoint inhibitors in late-stage melanoma patients.
Verkhovskaia S; Di Pietro FR; Mastroeni S; Carbone ML; Abeni D; Morese R; Morelli FM; D'Atri S; Marchetti P; De Galitiis F; Failla CM; Fortes C
J Cancer Res Clin Oncol; 2022 Sep; 148(9):2529-2538. PubMed ID: 34595541
[TBL] [Abstract][Full Text] [Related]
2. Vitiligo induced by immune checkpoint inhibitors in melanoma patients: an expert opinion.
Lommerts JE; Bekkenk MW; Luiten RM
Expert Opin Drug Saf; 2021 Aug; 20(8):883-888. PubMed ID: 33896329
[No Abstract] [Full Text] [Related]
3. Immune checkpoint inhibitor associated vitiligo and its impact on survival in patients with metastatic melanoma: an Italian Melanoma Intergroup study.
Guida M; Strippoli S; Maule M; Quaglino P; Ramondetta A; Chiaron Sileni V; Antonini Cappellini G; Queirolo P; Ridolfi L; Del Vecchio M; Cocorocchio E; Di Giacomo AM; Festino L; Merelli B; Occelli M; Brugnara S; Minisini A; Sava S; Tommasi S; De Summa S;
ESMO Open; 2021 Apr; 6(2):100064. PubMed ID: 33711672
[TBL] [Abstract][Full Text] [Related]
4. Immune checkpoint inhibitor-induced vitiligo in cancer patients: characterization and management.
Lo J; Hanania HL; Keiser MF; Patel AB
Arch Dermatol Res; 2023 Aug; 315(6):1697-1703. PubMed ID: 36809408
[TBL] [Abstract][Full Text] [Related]
5. Vitiligo expansion and extent correlate with durable response in anti-programmed death 1 antibody treatment for advanced melanoma: A multi-institutional retrospective study.
Matsuya T; Nakamura Y; Matsushita S; Tanaka R; Teramoto Y; Asami Y; Uehara J; Aoki M; Yamamura K; Nakamura Y; Fujisawa Y; Livingstone E; Zimmer L; Schadendorf D; Kagamu H; Fujimoto M; Honma M; Ishida-Yamamoto A; Araki R; Yamamoto A
J Dermatol; 2020 Jun; 47(6):629-635. PubMed ID: 32275100
[TBL] [Abstract][Full Text] [Related]
6. Vitiligo-like lesions developing upon immune checkpoint inhibition in advanced melanoma.
Grän F; Emmerich K; Mohme S; Goebeler M; Gesierich A
Eur J Dermatol; 2020 Feb; 30(1):72-73. PubMed ID: 32250264
[No Abstract] [Full Text] [Related]
7. Regression of nevi, vitiligo-like depigmentation and halo phenomenon may indicate response to immunotherapy and targeted therapy in melanoma.
Farinazzo E; Zelin E; Agozzino M; Papa G; Pizzichetta MA; di Meo N; Zalaudek I
Melanoma Res; 2021 Dec; 31(6):582-585. PubMed ID: 34433200
[TBL] [Abstract][Full Text] [Related]
8. Prevalence of dermatological toxicities in patients with melanoma undergoing immunotherapy: Systematic review and meta-analysis.
Mineiro Dos Santos Garrett NF; Carvalho da Costa AC; Barros Ferreira E; Damiani G; Diniz Dos Reis PE; Inocêncio Vasques C
PLoS One; 2021; 16(8):e0255716. PubMed ID: 34358260
[TBL] [Abstract][Full Text] [Related]
9. Melanoma and Vitiligo: In Good Company.
Failla CM; Carbone ML; Fortes C; Pagnanelli G; D'Atri S
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31731645
[TBL] [Abstract][Full Text] [Related]
10. Vitiligo-like Depigmentation in a Patient Undergoing Treatment with Nivolumab for Advanced Renal-cell Carcinoma.
Navarro-Fernandez I; Gonzalez-Vela C; Gomez-Fernandez C; Duran-Vian C; Reguero L; Gonzalez-Lopez M
Acta Dermatovenerol Croat; 2021 Apr; 291(1):54-55. PubMed ID: 34477066
[TBL] [Abstract][Full Text] [Related]
11. Panniculitis and vitiligo occurring during BRAF and MEK inhibitors combination in advanced melanoma patients: Potential predictive role of treatment efficacy.
Consoli F; Manganoni AM; Grisanti S; Petrelli F; Venturini M; Rangoni G; Guarneri F; Incardona P; Vermi W; Calzavara Pinton PG; Berruti A
PLoS One; 2019; 14(4):e0214884. PubMed ID: 30939167
[TBL] [Abstract][Full Text] [Related]
12. Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis.
Teulings HE; Limpens J; Jansen SN; Zwinderman AH; Reitsma JB; Spuls PI; Luiten RM
J Clin Oncol; 2015 Mar; 33(7):773-81. PubMed ID: 25605840
[TBL] [Abstract][Full Text] [Related]
13. Melanoma-associated leukoderma and vitiligo cannot be differentiated based on blinded assessment by experts in the field.
Lommerts JE; Teulings HE; Ezzedine K; van Geel N; Hartmann A; Speeckaert R; Spuls PI; Wolkerstorfer A; Luiten RM; Bekkenk MW
J Am Acad Dermatol; 2016 Dec; 75(6):1198-1204. PubMed ID: 27717621
[TBL] [Abstract][Full Text] [Related]
14. Vitiligo-specific soluble biomarkers as early indicators of response to immune checkpoint inhibitors in metastatic melanoma patients.
Carbone ML; Madonna G; Capone A; Bove M; Mastroeni S; Levati L; Capone M; Ascierto PA; De Galitiis F; D'Atri S; Fortes C; Volpe E; Failla CM
Sci Rep; 2022 Mar; 12(1):5448. PubMed ID: 35361879
[TBL] [Abstract][Full Text] [Related]
15. Vitiligo and Melanoma-Associated Vitiligo: Understanding Their Similarities and Differences.
Cohen BE; Manga P; Lin K; Elbuluk N
Am J Clin Dermatol; 2020 Oct; 21(5):669-680. PubMed ID: 32468356
[TBL] [Abstract][Full Text] [Related]
16. The association between immune checkpoint or BRAF/MEK inhibitor therapy and uveitis in patients with advanced cutaneous melanoma.
Dimitriou F; Urner-Bloch U; Eggenschwiler C; Mitsakakis N; Mangana J; Dummer R; Urner M
Eur J Cancer; 2021 Feb; 144():215-223. PubMed ID: 33373866
[TBL] [Abstract][Full Text] [Related]
17. Case Report: Immune checkpoint inhibitor-related vitiligo-like depigmentation in non-melanoma advanced cancer: A report of three cases and a pooled analysis of individual patient data.
Rao H; Guo Z; Wen X; Zeng X; Wu L; Huang L
Front Oncol; 2022; 12():1099108. PubMed ID: 36713515
[TBL] [Abstract][Full Text] [Related]
18. A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors.
Medri M; Savoia F; Foca F; Miserocchi A; Quaglino P; Rubatto M; Gullo G; Nardini C; Panasiti V; DE Tursi M; DI Marino P; Brancaccio G; Giunta EF; Napolitano S; Cinotti E; Brusasco M; Stanganelli I;
Ital J Dermatol Venerol; 2023 Dec; 158(6):437-444. PubMed ID: 38015482
[TBL] [Abstract][Full Text] [Related]
19. Cutaneous immune-related adverse events are associated with longer overall survival in advanced cancer patients on immune checkpoint inhibitors: A multi-institutional cohort study.
Zhang S; Tang K; Wan G; Nguyen N; Lu C; Ugwu-Dike P; Raval N; Seo J; Alexander NA; Jairath R; Phillipps J; Leung BW; Roster K; Chen W; Zubiri L; Boland G; Chen ST; Tsao H; Demehri S; LeBoeuf NR; Reynolds KL; Yu KH; Gusev A; Kwatra SG; Semenov YR
J Am Acad Dermatol; 2023 May; 88(5):1024-1032. PubMed ID: 36736626
[TBL] [Abstract][Full Text] [Related]
20. Cutaneous side effects and types of dermatological reactions in metastatic melanoma patients treated by immunotherapies or targeted therapies: A retrospective single center study.
Gullo G; Rubatto M; Fava P; Brizio M; Tonella L; Ribero S; Medri M; Avallone G; Mastorino L; Fierro MT; Stanganelli I; Quaglino P
Dermatol Ther; 2022 Jun; 35(6):e15492. PubMed ID: 35384181
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
